Clinical Safety of Chemotherapy for Elderly Cancer Patients Complicated with Hypertension

Abstract

Objective: To access the safety of chemotherapy for elderly cancer patients complicated with hypertension. Methods: Elderly cancer patients who were complicated with hypertension and treated by chemotherapy were recruited. All patients were treated by chemotherapy after an intervention on hypertension by psychotherapy, exercise guidance, salt regulation and nutrition support, therapy on hypertension, as well as prevention on hypertension associated complications. Results: In 68 eligible patients, two suspended chemotherapy because of adverse reactions and 4 because of disease progression. The remaining 62 patients completed chemotherapy smoothly based on good hypertension control. Conclusion: With effective control of blood pressure, chemotherapy for elderly cancer patients complicated with hypertension is generally safe.

Pathologic Response During Chemo-radiotherapy and Variation of Serum VEGF Levels Could Predict Effects of Chemo-Radiotherapy in Patients with Esophageal Cancer

“…The main method of treatment for cancer is multidisciplinary (Tian et al, 2014;Liu et al, 2014;Qian et al, 2014;Xiao et al, 2014). However, more than 60% of the patients cannot receive such surgery for medical reasons like local invasion and metastasis.…”

Clinical Investigation in Effect of Riboflavin Sodium Phosphate on Prevention and Treatment for Patients with Radiotherapy Related Esophagitis

“…The quality of life for these patients could be destroyed by clinical symptoms accompanied with radioactive esophagitis, eg., dysphagia or swallowing pain. However, conservative treatment is very difficult to achieve rapid recovery of RRE so that patients could not tolerate further treatment (Huang et al, 2014;Qian et al, 2014). As a consequence, an effective clinical method is urgently needed to prevent and treat RRE.…”

Adoptive Immunotherapy for Small Cell Lung Cancer by Expanded Activated Autologous Lymphocytes: a Retrospective Clinical Analysis

“…Previous reports have suggested that T-cells from non-tumorbearing hosts could boost the anti-tumor immunity to break the morbid equilibrium formed between tumor cells and the host (Vesely et al, 2013;Hosoi et al, 2014). Indeed, cell transfer therapy for cancer has been recognized as the fourth anticancer modality following the operation, chemotherapy and radiotherapy (Qian et al, 2014). However, the use of several immune cell types has been hampered by serious drawbacks including the poor efficacy and/or the complexity of cell propagation (Binsfeld et al, 2014;Kelderman et al, 2014;Weber et al, 2014).…”

“…Relapse even occurs in some patients within 3 months after the withdrawal of the first-line treatment. The second-line treatment can benefit the survival of patients (Qian et al, 2014). The first-line maintenance treatment or the increased dosage is unable to obviously reduce the relapses and improve the survival rates.…”